Stew Kroll
Theseus Pharmaceuticals (a subsidiary of Concentra Biosciences) · Jounce Therapeutics, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stew Kroll as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:49 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05160168 · A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Theseus Pharmaceuticals · terminated · Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue · study director
- Ph1/Ph2NCT04669899 · Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid TumorsJounce Therapeutics, Inc. · completed · Cancer · study director
- Ph2NCT04549025 · Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing RegimenJounce Therapeutics, Inc. · terminated · NSCLC · study director
- Ph1/Ph2NCT04319224 · Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid TumorsJounce Therapeutics, Inc. · terminated · Cancer · study director
- Ph1NCT03790488 · Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor MalignanciesJounce Therapeutics, Inc. · completed · Cancer · study director
- Ph1/Ph2NCT02904226 · JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsJounce Therapeutics, Inc. · completed · Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:49 UTC. The ranking covers the 200 most relevant of 42 PubMed records, and a shared surname and initials can bring in a namesake. All 42 on PubMed
- Angiotensin II for the Treatment of Vasodilatory Shock.N Engl J Med · 2017720 citationsRCR 31.9
- 131I-tositumomab therapy as initial treatment for follicular lymphoma.N Engl J Med · 2005530 citationsRCR 11.8
- A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.Cancer Chemother Pharmacol · 2013473 citationsRCR 12.3
- Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.J Clin Oncol · 2001455 citationsRCR 9.8
- 406 citationsRCR 8.4
- Timing of pedicle thrombosis and flap loss after free-tissue transfer.Plast Reconstr Surg · 1996367 citationsRCR 20.0
- 261 citationsRCR 8.4
- Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.J Clin Oncol · 2005198 citationsRCR 4.2
- 188 citationsRCR 4.1
- Reconstruction and the radiated breast: is there a role for implants?Plast Reconstr Surg · 1995185 citationsRCR 9.1